HLA-B and infection: In the Vax booster-M1 stage, it seems that serum from HLA-B*15 individuals displayed better viral neutralization efficacy than that from LVG individuals or non-HLA-B*15 (others), however, this effect was oppositely observed after BA.5.2 infection (BA.5.2-M1), and the neutralization efficiency of HLA-B*15 sera was reduced dramatically against the SARS-CoV-2 prototype strain and Gamma and Delta variants (Figure 3G), suggesting that sera from HLA-B*15 volunteers diminished viral neutralization efficacy after BA.5.2 infection.